eMedicine Specialties > Dermatology > Diseases of the Oral Mucosa

Oral Lymphangiomas: Treatment & Medication

Author: Sean P Edwards, DDS, MD, FRCD(C), Assistant Professor, Chief of Pediatric Oral and Maxillofacial Surgery, Section of Oral and Maxillofacial Surgery, Department of Surgery, C S Mott Children's Hospital, University of Michigan Medical Center
Coauthor(s): Joseph Helman, DMD, Clinical Professor and Chair, Department of Oral and Maxillofacial Surgery, University of Michigan
Contributor Information and Disclosures

Updated: Jun 16, 2009

Treatment

Medical Care

No appropriate medical care is available for oral lymphatic malformations, other than observation in selected patients. For example, a child with a superficial lesion without untoward functional sequelae may be observed. In all patients, address the perioperative airway, speech, and nutritional concerns.

  • Observation
    • Some authors advocate a period of watchful waiting in cases of asymptomatic lesions because a few reports show that the lesions regress spontaneously.
    • Other authors recommend excision as soon as the patient can safely tolerate a general anesthetic. These authors are concerned about the complications associated with untreated lesions and recognize the fact that repeated infections make future excision difficult.
  • Radiation therapy
    • Radiation therapy is of only historical interest.
    • This treatment should not be used because of its poor effectiveness, its multiple complications, and the risk of postradiation malignancies.

Surgical Care

Treatment of lymphatic malformations continues to evolve. Although surgical removal is overwhelmingly the most common modality used, sclerotherapy is being increasingly used to treat macrocystic lesions throughout the head and neck. Often the 2 modalities are combined for optimal outcomes. Determine the timing of intervention on a case-by-case basis. Lesions that impinge on the airway usually require the earliest intervention.

Isolated superficial malformations are often more of a nuisance than a debilitating condition. Given the fact that these are malformations and not true neoplasms and that they are entirely devoid of malignant potential, treatment should be aimed at maximizing the patient's function. In addition, treatment that results in a loss of function should not be tolerated. Early involvement of consultants can be helpful in meeting the goal of maximizing the patient's function and determining an optimal treatment plan.

  • Incision and drainage
    • Limit incision and drainage to emergent decompression of a lesion.
    • This procedure does not eliminate the lesion but decreases the risk of infection.
  • Surgical excision
    • Surgical excision remains the standard for treatment of lymphatic malformations, although many lesions are especially difficult to remove entirely because of their involvement with important neural and muscular structures; thus, these lesions are associated with the highest risk of recurrence and complications.
    • Recurrence rates of 20-40% are typically reported after surgical excision when the surgeon believes that the lesion is removed in its entirety.6
    • Complications of surgical excision of suprahyoid and oral lesions are also common. These operations can be difficult undertakings because of the diffuse infiltrative nature of the lesions and the difficulty in determining normal tissue from abnormal tissue.
    • Complication rates typically are 20-30%. Complications include airway obstruction, seromas and hematomas, infections, and cranial nerve palsies. Moreover, the reported operative mortality rates are 2.5-11.4%.
    • Surgical debulking, as part of a staged intervention plan, may be useful with large lingual malformations. Surgical debulking may obviate long-term tracheostomy, facilitate feeding, improve speech, and simplify further treatment, regardless of the modality used.
    • Surgical excision of macrocystic lesions may be facilitated by instilling fibrin glue into the cysts after partial aspiration of cystic contents.
  • Laser therapy
    • Surface laser photocoagulation is used as an adjunct for controlling the size of the tongue, treating superficial lesions, and controlling bleeding.
    • Good results are reported. With the exception of isolated superficial lesions, surface laser photocoagulation does not lead to a cure.
    • Repeated hospital admissions for laser photocoagulation are not unusual. Some patients undergo as many as 25 procedures, which can be a significant burden on the patient and his or her family. This consideration is important because the patient is already consulting with multiple specialists and undergoing multiple procedures.
    • Results appear to be equivalent regardless of whether carbon dioxide, argon, or Nd:YAG lasers are used.
  • Orthognathic surgery
    • Maxillofacial skeletal deformities and malocclusions should be treated with combined orthognathic and osteoplastic surgical procedures. Lesions of the upper part of the neck and, particularly, the floor of the mouth tend to be associated with bony overgrowth leading to class III malocclusions and open bite deformities. These lesions usually require combined surgical and orthodontic correction.
    • Orthognathic surgery is usually delayed until growth is complete, except in patients in whom the severity of the deformity necessitates earlier intervention.
  • Sclerotherapy7,8
    • Myriad agents are used as sclerosing agents in attempts to avoid surgery and its attendant problems or to treat remnant lesions after partial excision.
      • The use of bleomycin has produced some impressive results. Good or excellent results (ie, tumor disappeared and did not recur with 3-8 injections or fewer, respectively) occur in 75-100% of patients, depending on the dominant histologic pattern of the lesion. Pulmonary fibrosis (the worst complication) generally occurs only when cumulative doses exceed 450 mg. The 50-mg doses used in this therapy have not resulted in pulmonary fibrosis. Adverse effects include fever and anorexia lasting 24 hours in about 10% of patients. No adverse effects on growth and development are reported.
      • Tissucol, a fibrin sealant, is reported to induce a high rate of remission in lymphatic malformations. Adverse effects are not observed, though a potential for infectious disease transmission exists. Even superficial lesions can be successfully treated, although multiple injections (as many as 3) are often required.
      • Ethibloc, a synthetic sclerosing agent, has been used to induce lesion regression. The complete regression rate is 60%, with minimal complications.
      • OK-432, a lyophilized incubation mixture of group A Streptococcus pyogenes of human origin treated with penicillin G, has been in sclerotherapy since the mid-1980s. Total or marked shrinkage is observed in 67% of lesions. OK-432 stimulates an intense inflammatory response that causes cystic spaces to shrink and preserves the endothelium with no scar formation. OK-432 may enhance the permeability of the endothelium, facilitating decompression. Adverse effects include a transient fever for 2-3 days after the injection and irritation at the injection site.9
    • Repeated injections of sclerosing agents are often required, and resolution usually occurs over 1-4 months.
    • Macrocystic lesions are most amenable to sclerotherapy, followed by microcystic lesions and then superficial lesions.
    • Sclerotherapy does not represent an advantage compared with surgical ablation, with respect to success and ease of treatment. Success rates vary considerably depending on the agent used. Generally, boiling water, sodium morrhuate, tetracycline, 50% dextrose, and steroids are not effective in treating lymphatic malformations.
    • The encouraging results reported with sclerotherapy in conjunction with its low complication rate favor its adoption into the treatment protocols for lymphatic malformation, either as a stand-alone modality or as an adjunct to surgery.

Consultations

  • Anesthesiologist: Preoperative consultation with an anesthesiologist is often necessary for planning perioperative airway management.
  • Speech pathologist
    • Preoperative assessment by a speech pathologist can help in identifying patients with deranged swallowing mechanics and in optimizing speech patterns.
    • The speech pathologist's input can help determine the need for and timing of intervention.
    • Postoperative consultation is often necessary for correcting any accumulated speech pathology and for managing rehabilitation, which is particularly important when lesions involve the tongue and soft palate.
    • Early involvement of speech pathologists and audiologists can help in identifying problems early in the course of the disease (see Complications). These specialists can aid in optimizing the patient's treatment plan.
  • Pediatric dentist and orthodontist
    • Consultation is warranted to optimize the health and development of the patient's dentition.
    • Consultation with an orthodontist is warranted when orthognathic surgery is planned for the correction of maxillofacial skeletal deformities.
    • Pediatric dentists should be involved early in the care of children with oral lymphangiomas. Regular dental prophylaxis (q4-6mo) should be aggressively pursued to minimize the likelihood of developing an odontogenic source for infection of the malformation (see Complications).
  • Dietitian
    • Dietitians should address the perioperative feeding of the patient before surgery is performed.
    • A dietitian can help in educating the patient and his or her family.
  • Otolaryngologist and/or audiologist
    • Otolaryngologists are instrumental in the assessment and management of lesions involving the lower airway. Tracheostomy is required in as many as 50% of infants with cervicofacial lymphatic malformations. Tracheostomy places a tremendous burden on the child and family and, significantly, negatively impairs the child's quality of life. Decannulation should be aggressively pursued as part of the multidisciplinary management of the lesion.
    • When lesions involve the soft palate, the potential for eustachian tube dysfunction exists.
    • Because consultants may identify hearing deficits that could result, they aid in determining the need for and timing of intervention.

Diet

Depending on the location and size of the lesion, a variety of enteral feeding modalities may be required.

  • Short-term bypass feeding while convalescing from surgery is most easily accomplished by using a nasogastric feeding tube.
  • When prolonged (>4-6 wk) feeding difficulties are anticipated, a feeding gastrostomy is typically preferred.
  • When an oral diet is permitted, patients typically begin with a clear liquid diet until approximately 2 weeks after surgery or longer if complications delay wound healing.

Activity

Activity restrictions depend on the extent of the lesion.

  • Patients in whom only superficial lesions are removed do not require activity restriction.
  • Patients undergoing major debulking of larger lesions are generally advised to refrain from strenuous activity for approximately 4-6 weeks.

More on Oral Lymphangiomas

Overview: Oral Lymphangiomas
Differential Diagnoses & Workup: Oral Lymphangiomas
Treatment & Medication: Oral Lymphangiomas
Follow-up: Oral Lymphangiomas
Multimedia: Oral Lymphangiomas
References

References

  1. Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. Mar 1982;69(3):412-22. [Medline].

  2. Padwa BL, Hayward PG, Ferraro NF, Mulliken JB. Cervicofacial lymphatic malformation: clinical course, surgical intervention, and pathogenesis of skeletal hypertrophy. Plast Reconstr Surg. May 1995;95(6):951-60. [Medline].

  3. Tempero RM, Hannibal M, Finn LS, Manning SC, Cunningham ML, Perkins JA. Lymphocytopenia in children with lymphatic malformation. Arch Otolaryngol Head Neck Surg. Jan 2006;132(1):93-7. [Medline].

  4. Alqahtani A, Nguyen LT, Flageole H, Shaw K, Laberge JM. 25 years' experience with lymphangiomas in children. J Pediatr Surg. Jul 1999;34(7):1164-8. [Medline].

  5. Yonetsu K, Nakayama E, Kawazu T, Kanda S, Ozeki S, Shinohara M. Value of contrast-enhanced magnetic resonance imaging in differentiation of hemangiomas from lymphangiomas in the oral and maxillofacial region. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. Oct 1999;88(4):496-500. [Medline].

  6. Raveh E, de Jong AL, Taylor GP, Forte V. Prognostic factors in the treatment of lymphatic malformations. Arch Otolaryngol Head Neck Surg. Oct 1997;123(10):1061-5. [Medline].

  7. Bai Y, Jia J, Huang XX, Alsharif MJ, Zhao JH, Zhao YF. Sclerotherapy of microcystic lymphatic malformations in oral and facial regions. J Oral Maxillofac Surg. Feb 2009;67(2):251-6. [Medline].

  8. Burrows PE, Mitri RK, Alomari A, et al. Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol. 2008;6(3-4):209-16. [Medline].

  9. Greinwald JH, Burke DK, Sato Y, et al. Treatment of lymphangiomas in children: an update of Picibanil (OK-432) sclerotherapy. Otolaryngol Head Neck Surg. Oct 1999;121(4):381-7. [Medline].

  10. Edwards PD, Rahbar R, Ferraro NF, Burrows PE, Mulliken JB. Lymphatic malformation of the lingual base and oral floor. Plast Reconstr Surg. Jun 2005;115(7):1906-15. [Medline].

  11. Neville DD, Damm DD, Allen CM, Bouquot JE. Soft tissue tumors. In: Oral and Maxillofacial Pathology. ed. WB Saunders Co; 1995:711.

Further Reading

Keywords

cystic hygromas, lymphatic malformations, simple microcystic lesions, simple macrocystic lesions, cervicofacial lymphatic malformations, oral malformations, hamartomatous lesions, lymphangioma

Contributor Information and Disclosures

Author

Sean P Edwards, DDS, MD, FRCD(C), Assistant Professor, Chief of Pediatric Oral and Maxillofacial Surgery, Section of Oral and Maxillofacial Surgery, Department of Surgery, C S Mott Children's Hospital, University of Michigan Medical Center
Sean P Edwards, DDS, MD, FRCD(C) is a member of the following medical societies: Alpha Omega Alpha, American Association of Oral and Maxillofacial Surgeons, American Cleft Palate/Craniofacial Association, American Medical Association, International Association of Oral & Maxillofacial Surgeons, and Royal College of Dentists of Canada
Disclosure: Nothing to disclose.

Coauthor(s)

Joseph Helman, DMD, Clinical Professor and Chair, Department of Oral and Maxillofacial Surgery, University of Michigan
Joseph Helman, DMD is a member of the following medical societies: American Association of Oral and Maxillofacial Surgeons
Disclosure: Nothing to disclose.

Medical Editor

Smeena Khan, MD, Private Practice, Adult and Pediatric Dermatology Associates
Smeena Khan, MD is a member of the following medical societies: Alpha Omega Alpha and American Academy of Dermatology
Disclosure: Nothing to disclose.

Pharmacy Editor

David F Butler, MD, Professor of Dermatology, Texas A&M University College of Medicine; Chair, Department of Dermatology, Director, Dermatology Residency Training Program, Scott and White Clinic, Northside Clinic
David F Butler, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Association of Military Dermatologists, and Phi Beta Kappa
Disclosure: Nothing to disclose.

Managing Editor

Drore Eisen, MD, DDS, Consulting Staff, Department of Dermatology, Dermatology Research Associates of Cincinnati
Drore Eisen, MD, DDS is a member of the following medical societies: American Academy of Dermatology, American Academy of Oral Medicine, and American Dental Association
Disclosure: Nothing to disclose.

CME Editor

Glen H Crawford, MD, Assistant Clinical Professor, Department of Dermatology, University of Pennsylvania School of Medicine; Chief, Division of Dermatology, The Pennsylvania Hospital
Glen H Crawford, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Medical Association, Phi Beta Kappa, and Society of USAF Flight Surgeons
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.